Glutathione occurs naturally in the body, but that does not mean concentrated supplemental or injectable use is free of risk. This page outlines safety themes for educational purposes and is not medical advice.
The safety question is a route question
Asking "is glutathione safe" without specifying the route produces a useless answer. Oral glutathione at supplement doses has randomized tolerability data and looks unremarkable. Intravenous glutathione for cosmetic skin lightening has been singled out by dermatology systematic reviewers as contraindicated — not merely unproven. Those are two different safety conversations about the same molecule, and merging them is how the reassuring half gets used to cover the concerning half.
What the oral trial actually recorded
In the 12-week randomized, double-blind, placebo-controlled trial of oral glutathione — 60 enrolled, 57 completing, comparing GSH 250 mg/day, GSSG 250 mg/day, and placebo (Weschawalit et al., Clinical, Cosmetic and Investigational Dermatology, 2017; PMC5413479) — adverse effects were reported in 13.15% of the combined glutathione groups versus 21.05% of the placebo group. The events described were pruritus, erythema, red spots, and tiredness.
A treated arm reporting fewer adverse events than placebo is a signal that nothing much attributable to the compound was happening at that dose over that window. It is also a narrow window: 12 weeks, one dose level, and a population the authors describe as entirely female, Asian, and within a defined age range. It says nothing about years of use or about other routes.
The intravenous verdict
Three independent dermatology reviews reach the same conclusion about the intravenous route, and they are worth quoting rather than paraphrasing:
- A 2025 systematic review in the International Journal of Dermatology (PMID 39444151) found only a single placebo-controlled IV study and concluded that "IV glutathione is contraindicated due to lack of efficacy and side effects."
- A review in the Indian Journal of Dermatology, Venereology and Leprology (PMID 27088927) described intravenous glutathione as lacking efficacy evidence and noted that it prompted regulatory warnings from the Philippine FDA, with only three randomized trials supporting the topical and oral routes.
- A Journal of Cosmetic Dermatology review of systemic skin-lightening agents (PMID 30133125) listed oral glutathione among promising options while explicitly cautioning against the intravenous form on adverse-event grounds.
"Contraindicated" is a strong word in a systematic review, and it is directed at exactly the product being sold hardest.
Interactions and special populations
Because glutathione participates in phase II conjugation and redox handling, there is theoretical potential to interact with medicines whose activity depends on oxidative mechanisms — chemotherapy being the case most often raised. Controlled interaction data are limited, so this remains a reason for caution rather than a demonstrated hazard.
The trial populations that generated the tolerability data were small, healthy, and narrow. People who are pregnant or breastfeeding, who have significant medical conditions, or who take prescription medicines sit outside them entirely.
What remains uncharacterized
There is no large, long-term controlled trial of high-dose injectable or intravenous glutathione, which is why its risk profile is described in reviews by reference to case reports and regulatory action rather than to incidence rates. In the United States glutathione is sold as a dietary supplement and is not an FDA-approved drug for antioxidant, anti-aging, or skin-lightening indications, so no labeled safety section exists to consult. Product quality, sterile manufacturing, honest labeling, and clinical oversight carry more of the safety burden here than the molecule's own pharmacology does.